UBS Group
BXRX

UBS Group’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

UBS Group’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,844
Closed -$2.53K – 10582
2023
Q3 		$2.53K Sell
6,844
-2,812
-29% -$1.6K ﹤0.01% 7683
2023
Q2 		$11.3K Buy
+9,656
New +$9.22K ﹤0.01% 7110
2023
Q1 		– Sell
-3,011
Closed -$9.57K – 11550
2022
Q4 		$9.57K Buy
3,011
+1,077
+56% +$6.45K ﹤0.01% 8634
2022
Q3 		$19K Buy
1,934
+1,755
+980% +$40.8K ﹤0.01% 7499
2022
Q2 		$6K Buy
+179
New +$8.37K ﹤0.01% 8818
2022
Q1 		– Sell
-133
Closed -$41K – 11533
2021
Q4 		$41K Buy
133
+87
+189% +$54.5K ﹤0.01% 7105
2021
Q3 		$36K Buy
+46
New +$40K ﹤0.01% 6607
2021
Q2 		– Sell
-8
Closed -$14K – 10202
2021
Q1 		$14K Buy
+8
New +$16K ﹤0.01% 7706
2020
Q4 		– Sell
-6
Closed -$22K – 8981
2020
Q3 		$22K Buy
6
+2
+50% +$9.05K ﹤0.01% 6255
2020
Q2 		$25K Sell
4
-6
-60% -$28.8K ﹤0.01% 6415
2020
Q1 		$33K Hold
10
– – ﹤0.01% 6152
2019
Q4 		$92K Buy
+10
New +$85.3K ﹤0.01% 6047

UBS Group's BXRX Position: Q4 2023 in Review

UBS Group sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2023, closing a stake of 6,844 shares — an estimated $2.53K sold.

UBS Group first reported a position in BXRX in Q4 2019 and held it in 12 quarters. The position peaked at $92K in Q4 2019. 2 funds tracked by Wall St. Rank hold BXRX as of Q4 2023.

  • UBS Group reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 6,844 Baudax Bio, Inc. Common Stock shares in Q4 2023, an estimated $2.53K.
  • UBS Group first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
  • UBS Group's Baudax Bio, Inc. Common Stock position peaked at $92K in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.